Vernakalant Beats Procainamide for Rapid ED Cardioversion of Recent-Onset Atrial Fibrillation: Results from RAFF4
Highlights
– In the RAFF4 randomized clinical trial (n=350), vernakalant converted a greater proportion of patients to sinus rhythm within 30 minutes than procainamide (62.4% vs 48.3%; adjusted absolute difference 15.0%).
– Vernakalant achieved conversion faster (mean 21.8 vs 44.7 minutes) and reduced the need for attempted electrical cardioversion (33.7% vs 44.2%).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.